

## Open

# Microbiota of *De-Novo* Pediatric IBD: Increased *Faecalibacterium Prausnitzii* and Reduced Bacterial Diversity in Crohn's But Not in Ulcerative Colitis

Richard Hansen, MBChB<sup>1,2</sup>, Richard K. Russell, MBChB, PhD<sup>3</sup>, Caroline Reiff, PhD<sup>4</sup>, Petra Louis, PhD<sup>5</sup>, Freda McIntosh, BSc<sup>5</sup>, Susan H. Berry<sup>1</sup>, Indrani Mukhopadhyaya, PhD<sup>1</sup>, W. Michael Bisset, MBChB, MD<sup>6</sup>, Andy R. Barclay, MBChB, MD<sup>3</sup>, Jon Bishop, MBChB<sup>3</sup>, Diana M. Flynn, MBChB, PhD<sup>3</sup>, Paraic McGrogan, MBChB<sup>3</sup>, Sabarinathan Loganathan, MBChB<sup>6</sup>, Gamal Mahdi, MBChB<sup>6</sup>, Harry J. Flint, PhD<sup>5</sup>, Emad M. El-Omar, MBChB, MD<sup>1</sup> and Georgina L. Hold, PhD<sup>1</sup>

- OBJECTIVES:** The gastrointestinal microbiota is considered important in inflammatory bowel disease (IBD) pathogenesis. Discoveries from *established* disease cohorts report reduced bacterial diversity, changes in bacterial composition, and a protective role for *Faecalibacterium prausnitzii* in Crohn's disease (CD). The majority of studies to date are however potentially confounded by the effect of treatment and a reliance on established rather than *de-novo* disease.
- METHODS:** Microbial changes at diagnosis were examined by biopsying the colonic mucosa of 37 children: 25 with newly presenting, untreated IBD with active colitis (13 CD and 12 ulcerative colitis (UC)), and 12 pediatric controls with a macroscopically *and* microscopically normal colon. We utilized a dual-methodology approach with pyrosequencing (threshold >10,000 reads) and confirmatory real-time PCR (RT-PCR).
- RESULTS:** Threshold pyrosequencing output was obtained on 34 subjects (11 CD, 11 UC, 12 controls). No significant changes were noted at phylum level among the Bacteroidetes, Firmicutes, or Proteobacteria. A significant reduction in bacterial  $\alpha$ -diversity was noted in CD vs. controls by three methods (Shannon, Simpson, and phylogenetic diversity) but not in UC vs. controls. An *increase* in *Faecalibacterium* was observed in CD compared with controls by pyrosequencing (mean 16.7% vs. 9.1% of reads,  $P=0.02$ ) and replicated by specific *F. prausnitzii* RT-PCR (36.0% vs. 19.0% of total bacteria,  $P=0.02$ ). No disease-specific clustering was evident on principal components analysis.
- CONCLUSIONS:** Our results offer a comprehensive examination of the IBD mucosal microbiota at diagnosis, unaffected by therapeutic confounders or changes over time. Our results challenge the current model of a protective role for *F. prausnitzii* in CD, suggesting a more dynamic role for this organism than previously described.

**SUPPLEMENTARY MATERIAL** is linked to the online version of the paper at <http://www.nature.com/ajg>

*Am J Gastroenterol* 2012; 107:1913–1922; doi:10.1038/ajg.2012.335; published online 9 October 2012

## INTRODUCTION

Inflammatory bowel disease (IBD) comprises a group of disorders characterized by chronic intestinal inflammation with the main phenotypes being Crohn's disease (CD) and ulcerative colitis (UC). The incidence of IBD is rising, especially in children (1–3). Genetic discoveries implicate intracellular

bacterial recognition (NOD2) and mechanisms of intracellular bacterial handling such as autophagy (4,5). The importance of the host innate immune response to bacteria highlighted by these discoveries has resulted in a renewed interest in the intestinal microbiota in IBD. The microbiota fulfills important roles in immunological development, defense against pathogens,

<sup>1</sup>Gastrointestinal Research Group, Division of Applied Medicine, University of Aberdeen, Aberdeen, UK; <sup>2</sup>Child Health, Royal Aberdeen Children's Hospital, University of Aberdeen, Aberdeen, UK; <sup>3</sup>Department of Paediatric Gastroenterology, Royal Hospital for Sick Children, Glasgow, UK; <sup>4</sup>Max Planck Institute, Cologne, Germany; <sup>5</sup>Gut Health Programme, Rowett Institute, University of Aberdeen, Aberdeen, UK; <sup>6</sup>Department of Paediatric Gastroenterology, Royal Aberdeen Children's Hospital, Aberdeen, UK. **Correspondence:** Georgina L. Hold, PhD, Gastrointestinal Research Group, Division of Applied Medicine, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK. E-mail: [g.l.hold@abdn.ac.uk](mailto:g.l.hold@abdn.ac.uk)

Received 7 May 2012; accepted 13 August 2012

production of exogenous enzymes, and salvage of dietary energy (6,7). Studies on the microbiota of IBD have revealed changes in its composition, which are now part of the disease pathogenesis paradigm. These include an increase in bacterial numbers, a reduction in bacterial diversity, increases in the phyla Proteobacteria and Bacteroidetes, and a reduction in Firmicutes (8–11). The published evidence to date has relied on largely opportunistic studies of patients with established disease, providing a microbial snapshot of the chronic disease state at various time points after diagnosis. A significant limitation of this approach however is that the major confounders of active treatment and disease chronicity make it impossible to interpret events following on from disease initiation (12). The interrogation of the fecal microbiota in many studies also introduces a difficulty, as the mucosal and fecal bacterial ecosystems are recognized as being distinct in health, but with little known in disease states (13,14).

Pediatric IBD offers an opportunity to explore these problems, since children are relatively free of additional significant comorbidities and are generally treatment naïve at IBD diagnosis. For these reasons, we set up the “Bacteria in Inflammatory bowel disease in Scottish Children Undergoing Investigation before Treatment” (BISCUIT) study.

## METHODS

### Patient recruitment, biopsy collection, and processing

Patients were recruited to the BISCUIT study from routine colonoscopy lists in each of three pediatric centers (Royal Aberdeen Children’s Hospital, Aberdeen; Royal Hospital for Sick Children, Glasgow; and Ninewells Hospital, Dundee). An initial approach with study information was made either by post in advance of admission or on the day of admission, a minimum of 12 h in advance of the procedure. Patients under investigation in the pediatric centers were approached if the attending clinician deemed it possible that they would be found to have either IBD or a normal colon at colonoscopy. Patients were excluded if they had received systemic antibiotics or steroids in the 3 months before their colonoscopy or immunosuppression at any time, or if they had a previous diagnosis of IBD. All patients were investigated as per the Porto criteria, then diagnosed and phenotyped with reference to standard criteria (15–18).

Over 3 years the study recruited 100 children undergoing colonoscopy throughout Scotland in two categories, those with likely IBD, at first presentation, with macroscopic colonic inflammation ( $n=45$ ) and those undergoing colonoscopy who subsequently had a normal colon macroscopically ( $n=55$ ). The final IBD cohort comprised 44 confirmed IBD subjects (29 CD, 13 UC, and 2 IBD, type unclassified). The remaining “likely IBD” (inflamed colon) subject had mild, non-specific chronic inflammation in their distal colon on histopathology. This was insufficient to warrant a formal IBD diagnosis.

Biopsies were taken from a single site, from the distal colon in controls (rectum/sigmoid), or from the most distal inflamed site in IBD. In all, 2–3 biopsies were collected using standard endoscopic forceps. Biopsies were collected into a sterile 1.5 ml Eppendorf container and placed immediately onto ice before transfer to  $-80^{\circ}\text{C}$  storage.

To explore bacterial diversity, 37 subjects were identified for further analysis (Table 1; Supplementary Table 1). Twelve UC were included, all with distal colonic inflammation. Thirteen CD patients were identified with granulomatous change in their biopsy set, firmly supportive of their diagnosis, and distal colonic inflammation in keeping with CD (and hence distal colonic biopsies) to match colonic site with the control and UC cohorts. Twelve controls were selected as most representative of “normal,” having both a macroscopically *and* a microscopically normal colon, matched as closely as possible for age and sex to the IBD groups. None of the controls have gone on to develop IBD with a mean time since endoscopy of 23 months (minimum 7 months).

DNA extraction of mucosal biopsies was performed using the commercially available Qiagen QIAamp Mini kit (Qiagen, Crawley, UK) with minor modifications (19). A test PCR was performed as described previously with biopsy DNA utilizing primers universal for bacteria to confirm the suitability of the DNA for further analysis (20).

Ethical approval was granted by North of Scotland Research Ethics Service (09/S0802/24) on behalf of all participating centers and written informed consent was obtained from the parents of all subjects. Informed assent was also obtained from older children who were deemed capable of understanding the nature of the study.

This study is publicly registered on the United Kingdom Clinical Research Network Portfolio (9633).

### Preparation of samples for pyrosequencing

Biopsy DNA was quantified by Nanodrop mass spectrophotometry before dilution to 25 ng/ $\mu\text{l}$ . Initial PCR amplification was undertaken with FastStart High Fidelity PCR reagents (Roche, Penzberg, Germany) utilizing a per-reaction mix of 50 ng of DNA template, 10 $\times$  FastStart High Fidelity Reaction Buffer with 90 nM  $\text{MgCl}_2$ , 10 nM dNTPs, 10 pM Fusion Primer A, 10 pM Fusion Primer B, 5 U FastStart High Fidelity Enzyme Blend. The 16S rDNA primers were taken from Dethlefsen *et al.* (21); however, we utilized the 338f partnered with 1064r, spanning the V3–V6 region of the 16S rRNA gene and providing a  $\sim 726$ -bp product. For the forward primer, two multiplex identifiers (MID1 and MID2) were used to allow multiplexing of paired samples during sequencing. No identifier was added to the reverse primer. Hence, the  $\sim 726$ -bp PCR product was flanked by a 40-bp fusion primer/multiplex identifier sequence at the forward end and a 30-bp fusion primer at the reverse end therefore resulting in a  $\sim 796$ -bp sequence. The final primers were A-338f1 5'-**CCATCTCATCCCTGCGTGTCTCCGACTCAGACGAGT**GCGTACTCCTACGGGAGGCAGCAG-3'; A-338f2 5'-**CCATCTCATCCCTGCGTGTCTCCGACTCAGACGCTCGACA**ACTCCTACGGGAGGCAGCAG-3' and B-1064r 5'-**CCTATCCCCTGTGTGCCTTGGCAGTCTCAGCGACARCCATG**CASCACCT-3' (page-purified primers by Sigma-Aldrich, Gillingham, UK) with the bold sections corresponding to fusion primers, the underlined sections multiplex identifiers, and the standard text to the 16S primers.

PCR cycling conditions were taken from the modified conditions of Dethlefsen and were briefly as follows: 3 min at  $94^{\circ}\text{C}$ ; 30 cycles of 30 s at  $94^{\circ}\text{C}$ , 45 s at  $55^{\circ}\text{C}$ , 60 s at  $72^{\circ}\text{C}$ ; 2 min at  $72^{\circ}\text{C}$  (21). After confirmation of successful PCR amplification, products were

**Table 1.** Statistical comparisons of study group demographics of original and final cohort

Original cohort	Controls (n=12) Median (Min to Max)	Crohn's (n=13) Median (Min to Max)	UC (n=12) Median (Min to Max)	All (n=37) Median (Min to Max)	Statistical comparison (Mann-Whitney U test unless indicated)		
					Control vs. Crohn's	Control vs. UC	Crohn's vs. UC
Age	11.4 (6.3 to 15.3)	12.2 (8.0 to 16.3)	13.0 (8.5 to 15.8)	12.2 (6.3 to 16.3)	0.140	0.424	0.533
Male:female	8:4	10:3	9:3	27:10	0.673 <sup>a</sup>	1.00 <sup>a</sup>	1.00 <sup>a</sup>
Height Z-score	0.1 (-0.4 to 2.1)	-0.7 (-2.5 to 1.9)	0.3 (-1.7 to 2.8)	0.1 (-2.5 to 2.8)	0.176	0.902	0.279
Weight Z-score	1.1 (-0.7 to 2.3)	-1.1 (-2.5 to 2.6)	0.0 (-1.6 to 1.8)	0.1 (-2.5 to 2.6)	<b>0.023</b>	<b>0.049</b>	0.140
BMI Z-score	1.1 (-0.7 to 2.2)	-0.9 (-3.7 to 2.8)	-0.1 (-2.2 to 1.7)	0.3 (-3.7 to 2.8)	<b>0.007</b>	<b>0.031</b>	0.622
Symptom duration (months)	12 (0 <sup>b</sup> to 36)	6 (1.5 to 21)	4.5 (0.5 to 36)	7 (0 to 36)	<b>0.044</b>	0.060	0.429
Final cohort	Controls (n=12) Median (Min to Max)	Crohn's (n=11) Median (Min to Max)	UC (n=11) Median (Min to Max)	All (n=34) Median (Min to Max)	Control vs. Crohn's	Control vs. UC	Crohn's vs. UC
Age	11.4 (6.3 to 15.3)	14.2 (8.0 to 16.3)	13.0 (8.5 to 15.8)	13.0 (6.3 to 16.3)	0.192	0.525	0.550
Male:female	8:4	8:3	8:3	24:10	1.00 <sup>a</sup>	1.00 <sup>a</sup>	1.00 <sup>a</sup>
Height Z-score	0.1 (-0.4 to 2.1)	-0.7 (-2.5 to 1.9)	0.5 (-1.7 to 2.8)	0.1 (-2.5 to 2.8)	0.073	0.644	0.301
Weight Z-score	1.1 (-0.7 to 2.3)	-1.2 (-2.5 to 2.6)	0.1 (-1.6 to 1.8)	0.2 (-2.5 to 2.6)	<b>0.011</b>	<b>0.033</b>	0.128
BMI Z-score	1.1 (-0.7 to 2.2)	-1.0 (-3.7 to 2.8)	-0.6 (-2.2 to 1.7)	0.2 (-3.7 to 2.8)	<b>0.004</b>	<b>0.033</b>	0.550
Symptom duration (months)	12 (0 <sup>b</sup> to 36)	6 (3 to 21)	5 (0.5 to 36)	7 (0 to 36)	0.064	0.089	0.449

BMI, body mass index; UC, ulcerative colitis.

*P* < 0.05 indicated by bold font.

<sup>a</sup>Fisher's exact test.

<sup>b</sup>Single asymptomatic patient undergoing colonoscopy for genetic risk of familial adenomatous polyposis coli. Next shortest symptom duration is 5 months.

purified as per the recommended Agencourt AMPure (Beckman Coulter, Beverly, MA) purification method for 454 sequencing and sequenced on Roche 454 Titanium (454 Life Sciences, Branford, CT) by NewGene (Newcastle, UK).

### Real-time PCR

Quantitative real-time PCR (RT-PCR) was performed as described previously (22). Briefly, standard curves consisted of 10-fold dilution series of amplified bacterial 16S rRNA genes from reference strains. Samples were amplified with universal primers against total bacteria and specific primers against *Bacteroidetes*, Firmicutes clostridial cluster IV, Firmicutes clostridial cluster XIVa, *Enterobacteriaceae* and *Faecalibacterium prausnitzii* (Table 2).

### Supplementary methods

**Supplementary Methods** contain additional detail on RT-PCR methodology, bioinformatic analysis of pyrosequencing data, and statistical analyses.

## RESULTS

Pyrosequencing generated >1 million individual sequencing reads in total with a mean yield of 21,691 reads per subject

after bioinformatic processing but before rarefaction (**Supplementary Table 2**). Of the 37 subjects in the study, 2 did not meet the 10,000 read threshold and were excluded, 1 UC whose bacterial DNA amplified poorly and failed quality control for pyrosequencing and 1 CD who was sequenced as all other subjects, but who only yielded 739 reads. In all, 1 further subject (CD) was sequenced and rarefied alongside the final 34, but 99.9% of their 11,000 reads were unmatched at phylum level. Thus, 34 subjects were ultimately represented by 11,000 rarefied reads after bioinformatic processing, allowing subject-to-subject comparison. The only resultant demographic change was a loss of significance in symptom duration between CD and controls (Table 1).

In all, 1 UC subject amplified poorly by RT-PCR despite successful pyrosequencing of their sample yielding 24,240 reads. A further attempt at RT-PCR with 50 ng DNA template was also unsuccessful; therefore, this subject was not included in RT-PCR correlations (*n* = 33) but was included in pyrosequencing analyses (*n* = 34). Pyrosequencing findings correlated with RT-PCR results to a 0.01 significance level (Pearson coefficients: *Bacteroidetes* 0.624 (*n* = 33), Firmicutes 0.571 (*n* = 33), Proteobacteria 0.891 (*n* = 20, restricted to those where Proteobacteria were above RT-PCR detection threshold)).

Bacterial diversity was significantly reduced in CD when compared with controls by three distinct indices (Shannon, Simpson, and Phylogenetic Diversity). No significant difference in bacterial diversity was noted between UC and controls by any of the five indices tested (Table 3).

Phylum-level diversity comparisons revealed no statistically significant differences for the three prevalent bacterial phyla of Bacteroidetes, Firmicutes, and Proteobacteria ( $P=0.142-0.850$ , ANOVA; Figure 1a-c; Table 4) and a significant result only in the numerically small phylum Actinobacteria between CD and controls (Table 4). Individual subject phylum-level diversity

showed some variability, particularly within Proteobacteria in UC (Figure 1d). Interestingly, a greater proportion of IBD reads were unmatched at phylum level, although these did not reach significance. Diversity comparisons by RT-PCR also revealed no statistically significant differences for *Bacteroidetes*, Clostridial Cluster XIVa or *Enterobacteriaceae* ( $P=0.215-0.619$ , ANOVA; Table 4), but did demonstrate a significant increase in Clostridial Cluster IV in CD vs. controls ( $P=0.029$ ).

An additional ANOVA comparison was made between each of the three pairings (CD vs. Controls, UC vs. controls, and CD vs. UC) against the top 99.9% of genus-level matches (78 genera). Of a possible 234 comparisons, only 7 achieved statistical significance. These were *Faecalibacterium*, CD>Controls (mean 1,841.1 ( $\pm 1,004.6$ ) vs. 921.7 ( $\pm 794.8$ ) reads,  $P=0.023$ ); *Parabacteroides*, Control>UC (mean 406.0 ( $\pm 427.9$ ) vs. 113.6 ( $\pm 87.8$ ) reads,  $P=0.038$ ); *Roseburia*, UC>CD (mean 159.2 ( $\pm 171.2$ ) vs. 37.0 ( $\pm 30.0$ ) reads,  $P=0.030$ ); *Burkholderiales* (/Other/Other), Control>UC (mean 53.3 ( $\pm 58.2$ ) vs. 5.1 ( $\pm 8.1$ ) reads,  $P=0.013$ ); *Prevotellaceae* (/Other), UC>CD (mean 21.8 ( $\pm 25.5$ ) vs. 2.7 ( $\pm 3.7$ ) reads,  $P=0.023$ ); *Desulfovibrio*, UC>CD (mean 21.5 ( $\pm 25.3$ ) vs. 2.7 ( $\pm 3.1$ ),  $P=0.024$ ); and *Coriobacteriaceae*, Control>CD (mean 15.7 ( $\pm 16.9$ ) vs. 2.7 ( $\pm 2.9$ ),  $P=0.021$ ).

The *Faecalibacterium* finding (1,841.1 reads (16.7% of all reads) from CD vs. 1,004.6 reads (8.4% of all reads) from controls,  $P=0.02$ ) was replicated with *F. prausnitzii*-specific RT-PCR (correlated with a 0.01 significance level with pyrosequencing data with a Pearson coefficient of 0.894,  $n=33$ ), which revealed mean prevalence of 36.0 ( $\pm 18.1$ )% of all bacteria in CD vs. 19.0 ( $\pm 14.1$ )% in controls ( $P=0.02$ ). Prevalence in UC was similar to controls by both methods (pyrosequencing from ANOVA: 10.1 ( $\pm 11.9$ )% of UC reads vs. 8.4 ( $\pm 7.2$ )% of controls,  $F=0.187$ ,  $P=0.7$ ; RT-PCR by *t*-test: 25.5 ( $\pm 26.7$ )% of UC reads vs. 19.0 ( $\pm 14.1$ )% of controls,  $P=0.5$ ) (Figure 2). The difference between CD and UC did not reach statistical significance by either method (pyrosequencing  $P=0.16$ , RT-PCR  $P=0.3$ ).

To explore clustering within disease categories, principal components analysis (PCA) was undertaken on weighted Unifrac distances (Figure 3). Interestingly, no distinct group clustering was observed within any phenotypic group. Although microbial diversity was significantly reduced in CD, this was not reflected by distinct clustering of CD subjects on PCA.

**Table 2. Real-time PCR primers used in this study**

Target group	Primer name	Primer sequence	Reference
All bacteria	UniF	GTGSTGCAYGGY YGTCGTCA	Ramirez-Farias <i>et al.</i> (22)
	UniR	ACGTCRTCCMCN CCTTCTC	
<i>Bacteroidetes</i>	Bac303F	GAAGGTCCCC ACATTG	
	Bfr-Fmrev	CGCKACTTGGC TGGTTCAG	
Clostridial cluster XIVa	Erec482F	CGGTACCTGA CTAAGAAGC	
	Erec870R	AGTTYATTCT TGCGAACG	
Clostridial cluster IV	Clep866mF	TTAACACAATAAG TWATCCACCTGG	
	Clept1240mR	ACCTTCCTCCG TTTTGTCAAC	
<i>Faecalibacterium prausnitzii</i>	FPR-2F	GGAGGAAGAA GGTCTTCGG	
	Fprau645R	AATCCGCCTA CCTCTGCACT	
<i>Enterobacteriaceae</i> <sup>a</sup>	Enterobact Dmod2F	GACCTCGCG AGAGCA	Walker <i>et al.</i> (47), modified
	Enter1432mod	CCTACTTCTTT TGCAACCCA	Sghir <i>et al.</i> (48), modified


<sup>a</sup>Amplification conditions as described in Ramirez-Farias *et al.* (22), with primer annealing temperature of 63°C and extension at 72°C for 30s.

**Table 3. Indices of bacterial  $\alpha$ -diversity from pyrosequencing data**

	Control	Crohn's	UC	Statistical comparison by <i>t</i> -test		
	Mean ( $\pm$ standard deviation)			Control vs. Crohn's	Control vs. UC	Crohn's vs. UC
Shannon	<b>5.59 (<math>\pm 0.30</math>)</b>	<b>5.15 (<math>\pm 0.46</math>)</b>	5.54 ( $\pm 0.64$ )	<b>0.017</b>	0.835	0.119
Simpson	<b>0.96 (<math>\pm 0.01</math>)</b>	<b>0.93 (<math>\pm 0.04</math>)</b>	0.94 ( $\pm 0.04$ )	<b>0.042</b>	0.227	0.429
Chao 1	448.6 ( $\pm 103.2$ )	428.0 ( $\pm 194.4$ )	552.0 ( $\pm 286.5$ )	0.758	0.279	0.251
Observed species	273.9 ( $\pm 42.7$ )	275.7 ( $\pm 79.7$ )	317.3 ( $\pm 124.6$ )	0.947	0.294	0.365
Phylogenetic diversity	<b>24.5 (<math>\pm 7.9</math>)</b>	<b>17.0 (<math>\pm 4.6</math>)</b>	<b>24.0 (<math>\pm 7.7</math>)</b>	<b>0.012</b>	0.882	<b>0.019</b>

UC, ulcerative colitis.

$P < 0.05$  indicated by bold font.



**Figure 1.** Phylum-level diversity assessment. (a–c) Pie charts comprised all patient rarefied reads (11,000 reads per patient) to represent overall diversity of each cohort; phyla comprising <1% have been removed for clarity. (a) Normal colon controls comprising 12 patients. (b) Crohn's disease comprising 11 patients. (c) Ulcerative colitis (UC) comprising 11 patients. (d) Individual patient diversity at phylum level as stacked bars. Individual patient data are presented in **Supplementary Table 1**. Spirochetes were identified in a single Control patient (BISCUIT number 45) and were not noted on histopathology. No Bacteroidetes were identified in a single UC patient (BISCUIT number 25). BISCUIT, Bacteria in Inflammatory bowel disease in Scottish Children Undergoing Investigation before Treatment.

## DISCUSSION

Our data describe a previously unexplored epoch in IBD microbiology, namely the onset of disease in treatment naïve children. A single adult study at IBD onset noted a significant difference in unclassified Bacteroidetes between CD and both UC and control patients, but no other significant phylum changes when intestinal biopsies were examined by denaturing gradient gel electrophoresis and clone libraries (23). Our study remains unique in the IBD literature by addressing the mucosal microbiota at the onset of disease in a population of treatment naïve children utilizing a deep sequencing approach, corroborated by RT-PCR. Our data challenge the view that phylum-level changes are important in IBD etiology, cast doubt on the notion that a reduction in bacterial diversity occurs in UC, but firmly support this same hypothesis in CD, thus demonstrating an important microbial distinction between these two conditions. Our bacterial diversity results probably indicate a true reduction associated with CD, as

both the CD and UC samples were obtained from inflamed tissue; hence, the reduction is not simply an artifact of inflammation. Interestingly, a similar reduction in bacterial diversity has recently been noted in the oral microbiota of children with CD, but not in those with UC or healthy children (24). Adult studies examining biopsies from both active and quiescent UC suggest a reduction in bacterial diversity in the former (25,26). Our UC cohort have active inflammation and are untreated, suggesting that the causative agent of a reduction in bacterial diversity is perhaps more complex than simply the presence of inflammation.

PCA, a useful method of comparing diversity between individuals and looking for disease-specific microbial clustering, showed no clear distinctions between each of the three phenotypes we have studied (controls, CD, and UC). The landmark paper by Frank *et al.* (27) utilizing PCA in adult IBD biopsies outlined nominal sample clusters between an IBD subset and a control subset, nevertheless the phenotypic distinction on PCA was not absolute. Others


**Table 4.** Phylum-level statistical comparisons for pyrosequencing data against equivalent RT-PCR

Pyrosequencing	Control	Crohn's	UC	Statistical Comparison by ANOVA					
				Control vs. Crohn's		Control vs. UC		Crohn's vs. UC	
				F	P	F	P	F	P
Actinobacteria	<b>0.5 (±0.4)</b>	<b>0.2 (±0.1)</b>	0.4 (±0.3)	<b>4.371</b>	<b>0.049</b>	0.258	0.617	3.516	0.075
Bacteroidetes	41.4 (±17.0)	34.9 (±11.0)	30.5 (±17.1)	1.176	0.291	2.333	0.142	0.500	0.488
Firmicutes	42.5 (±15.3)	45.3 (±14.6)	43.8 (±16.2)	0.198	0.661	0.037	0.850	0.053	0.820
Fusobacteria	0.1 (±0.2)	0.1 (±0.1)	0.5 (±1.1)	0.003	0.956	1.629	0.216	1.524	0.231
Proteobacteria	6.1 (±4.4)	4.9 (±2.1)	10.1 (±10.7)	0.616	0.441	1.480	0.237	2.545	0.126
Verrucomicrobia	0.3 (±1.0)	0.3 (±1.1)	0.2 (±0.6)	0.001	0.973	0.077	0.784	0.084	0.775
"Other"	7.3 (±7.2)	14.3 (±12.3)	14.4 (±17.7)	2.832	0.107	1.656	0.212	0.000	0.984
<b>RT-PCR</b>	<b>Mean percentage of all bacteria (±standard deviation)</b>								
<i>Bacteroidetes</i>	39.4 (±19.5)	30.9 (±10.7)	27.7 (±7.0)	1.632	0.215	2.898	0.105	0.575	0.458
Clostridial cluster IV	<b>22.2 (±15.7)</b>	<b>37.6 (±15.8)</b>	26.6 (±25.7)	<b>5.494</b>	<b>0.029</b>	0.241	0.629	1.431	0.244
Clostridial cluster XIVa	22.9 (±13.5)	28.3 (±9.7)	22.3 (±13.1)	1.200	0.286	0.011	0.919	1.443	0.246
<i>Enterobacteriaceae</i>	3.3 (±1.5)	2.8 (±1.8)	5.8 (±4.2)	0.277	0.609	1.918	0.193	3.040	0.107

UC, ulcerative colitis.

*P*<0.05 indicated by bold font.

Six ANOVA analyses were performed comprising each of the three possible pairings (control vs. Crohn's; control vs. UC; Crohn's vs. UC) and both methodologies (pyrosequencing and RT-PCR).



**Figure 2.** Comparison of mean prevalence (±standard deviation) of *Faecalibacterium* genus by pyrosequencing and *Faecalibacterium prausnitzii* by real-time PCR against all bacteria in the distal colon of children with a normal colon, Crohn's disease, and ulcerative colitis.

such as Walker *et al.* (28) have shown clear distinctions between disease phenotype using similar methods. The lack of differentiation we have shown suggests evolution as disease enters chronicity, or perhaps that such differentiation is merely an artifact of disease-specific treatment strategies.


We propose that the current literature on IBD microbiology more accurately reflects changes associated with disease chronicity, and as such should not be extrapolated to the onset of disease. Furthermore, the important issue of active treatment, which is

problematic when studying established disease, adds an important confounder which is underemphasized in the published literature.

In our study, all subjects received stimulant bowel preparation before colonoscopy. This may have altered the microbial profile of the colonic mucosa, however since the treatment was given to all, this would likely act equivalently between groups. Furthermore, the organisms least likely to be affected would be those with adherent properties, of most interest in the mucosal disease of IBD. In support of our approach, other investigators have demonstrated differences in the IBD microbiota despite prior bowel preparation (10,29). Finally, a study design where children undergo diagnostic colonoscopy under general anesthetic without adequate preparation would be ethically unacceptable. Related to this latter point, the controls in this study were children undergoing colonoscopy to investigate gastrointestinal symptoms. They were not therefore strictly "healthy" controls; however, we have tried to address this by selecting only those with a macroscopically and microscopically normal colon for inclusion.

Although genetically similar (30), there are important distinctions between adult and pediatric IBD with the latter being characterized by a more extensive phenotype (31) and, at least in the case of CD, by a distinct immunophenotype (32). Environmental factors such as gastrointestinal microbial colonization may be etiological factors of relevance to this distinction; hence, it is entirely possible that pediatric IBD is defined by a unique microbial signature, distinct from the adult disease.

Irrespective of the lack of phylum-level changes seen in our results at diagnosis, it appears that fecal microbial changes can be used as a useful biomarker for disease progression in children with



**Figure 3.** Principal components analysis (PCA) of weighted Unifrac distances for denoised, chimera-checked pyrosequencing data with 97% (top) and 95% (bottom) OTU clustering demonstrating PCA 1 vs. PCA 2 for normal colon controls, Crohn's disease, and ulcerative colitis. No distinct clustering is seen within phenotypic groups.

UC (33). The study of Michail *et al.* (33) demonstrated alterations in the fecal microbiota of pediatric UC vs. healthy controls, but also showed that UC non-responders to steroid treatment demonstrated fewer phylotypes within their fecal samples compared with responders when examined by microarray. This study raises an interesting consideration regarding microbial findings in IBD, since the alterations seen could reflect either causation or proxy association; nevertheless, their clinical utility as a biomarker may be sufficient alone to warrant their further exploration. Our own UC results were surprisingly similar to our normal colon control group, suggesting that the UC-specific fecal alterations described by Michail *et al.* may reflect an influence on the fecal stream rather

than on gastrointestinal colonization *per se*. Two explanations might be increased gastrointestinal transit (diarrhea) and anorexia in active UC. Understanding the impact of such influences and separating them from true etiological factors is a significant challenge in gastrointestinal community microbiology.

Perhaps of most interest, we demonstrated a significant increase in *F. prausnitzii* in CD at diagnosis, in marked contrast with previous reports of a reduction in the species in adult CD (29,34,35).

*F. prausnitzii* is likely to have an important role in CD; however, its role may be more complex than our current understanding. It is clear from the seminal study of Sokol *et al.* (34) that this single species is positively associated with an improved

outcome in established adult CD, with the demonstration that reduction in the proportion of this bacterium in intestinal samples was associated with endoscopic recurrence of disease. The same paper demonstrated the anti-inflammatory properties of the bacterium in both a human *in vitro* cell model and a murine *in vivo* colitis model (34). The inference of course is that the reduction of *F. prausnitzii* in CD is not simply a proxy for worsening inflammation/disease, but that the organism is an integral component of the anti-inflammatory balance in health and its reduction may directly contribute to promotion of the disease state. Our data directly contradict this hypothesis. One possible explanation might be highlighted by *Bacteroides fragilis*, an organism found to be capable of initiating colitis in animal models (36), but also of directing an anti-inflammatory immune response (37,38). Individual components of the microbiota may thus fulfill differing roles under different conditions. Whether the increase in *F. prausnitzii* seen in CD within our study represents a hitherto undescribed pro-inflammatory role for the species, whether the early host/microbiota response to IBD induces proliferation of *F. prausnitzii* in an attempt to reverse the inflammatory change or whether the changes seen here are a proxy for some other phenomenon remains to be explained.

A single study from Jia *et al.* (39) reported a correlation between clinical improvement and a reduction in fecal *F. prausnitzii* abundance in patients with CD who responded to enteral nutrition therapy. The authors explained their surprising *F. prausnitzii* observation by commenting that it may merely be an innocent bystander in CD. Our data using more robust methodology are the first to demonstrate an increase in this bacterium at CD diagnosis, which suggests a more complex and integral role for *F. prausnitzii* in CD pathogenesis. Interestingly, the data of Willing *et al.* (29), derived from pyrosequencing of fecal samples in established disease, demonstrated an increase in *Faecalibacterium* in colonic, but a reduction in ileal CD although the former was not elaborated fully on within the paper.

Enteral nutrition is widely used in the management of pediatric CD, achieving high rates of remission in all phenotypes (40). Its mode of action remains to be explained fully, although published studies to date suggest that changes in the microbiota parallel clinical response (41). A recent study demonstrated a reduction in fecal *F. prausnitzii* in healthy adults fed a low fiber enteral feed (42). Considering this paper in tandem with our results, one could hypothesize that enteral nutrition results in a temporary reduction of bacterial load, especially *F. prausnitzii* whose growth is known to be stimulated by acetate produced by other bacteria, as well as by substrates supplied from a normal balanced diet. This could in turn lead to a temporary remission from CD activity. This hypothesis would fit with the transient nature of enteral nutrition-induced remission in pediatric CD, with 60–70% of patients relapsing within 12 months of cessation (43).

Another possible mechanism is suggested by very recent evidence that *F. prausnitzii*, although hitherto regarded as a strict anaerobe, has the ability to use low concentrations of oxygen as an electron acceptor through extracellular electron transfer (44). It is proposed that this ability may equip *F. prausnitzii* for survival at the interface between oxygenated and anaerobic zones close to

the colonic wall, which appears consistent with the high representation of *F. prausnitzii* noted here in biopsy samples. Disturbance to the colonic mucosa and mucus layer in disease states is likely to affect local oxygen gradients, with consequences for *F. prausnitzii* populations.

Our study has generated novel and intriguing data especially with regard to *F. prausnitzii* however larger prospective follow-up studies, with serial sampling of the mucosal microbiota at diagnosis and at opportunistic times throughout treatment, would further improve our understanding of the microbiology of these chronic diseases. Such studies would lend important insight into longitudinal microbial changes and their relationship with the potential confounders outlined above, hopefully helping to explain the complexities of the IBD microbiota and important organisms such as *F. prausnitzii*, with direct implications for disease treatment. The recent publication of data from the Human Microbiome Project has clearly shown the abundance, diversity and physiological importance of our microbial cohabitants and provided scaffolding for future studies (45,46). A greater understanding of the microbial pathogenesis of IBD is now within our grasp.

#### ACKNOWLEDGMENTS

We are grateful for the expertise of our sequencing provider NewGene and in particular for the support and help of Dr Jonathan Coxhead. Mrs Karen McIntyre and Dr Dagmar Kastner were invaluable in identifying patients for recruitment in Dundee. Mrs Ann Morrice provided administrative support in Aberdeen. Dr Paul Henderson gave helpful comments on the manuscript. We appreciate the generosity of the families who freely gave their time and samples to make this study possible and the theatre staff of all centers who allowed time for sample collection during busy endoscopy lists.

#### CONFLICT OF INTEREST

**Guarantor of the article:** Georgina L. Hold, PhD.

**Specific author contributions:** Designed the study: Richard Hansen, Emad M. El-Omar, Georgina L. Hold, Caroline Reiff, and Richard K. Russell; study coordinator: Richard Hansen; identified and recruited patients for the study: Richard Hansen, Richard K. Russell, W. Michael Bisset, Andy R. Barclay, Jon Bishop, Diana M. Flynn, Paraic McGrogan, Sabarinathan Loganathan and Gamal Mahdi; undertook the experiments: Richard Hansen, Petra Louis, Freda McIntosh, Susan H. Berry, Indrani Mukhopadhyaya, and Georgina L. Hold; performed bioinformatic analysis of the sequencing data: Caroline Reiff; performed statistical analyses: Richard Hansen; wrote the manuscript: Richard Hansen, Georgina L. Hold, Caroline Reiff, Petra Louis, Richard K. Russell, and Emad M. El-Omar; all authors reviewed it and agreed on the final version.

**Financial support:** This work was funded by a Clinical Academic Training Fellowship from the Chief Scientist Office in Scotland (CAF/08/01) which also funded the salary of RH and a project grant from Crohn's in Childhood Research Association (CICRA). The Royal Hospital for Sick Children, Glasgow IBD team is generously supported by the Catherine McEwan Foundation and the Yorkhill IBD fund. RKR is supported by an NHS Research Scotland

career fellowship award. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Potential competing interests:** None.

## Study Highlights

### WHAT IS CURRENT KNOWLEDGE

- ✓ The intestinal microbiota is considered as pivotal in inflammatory bowel disease (IBD) pathogenesis.
- ✓ Established adult IBD is associated with microbial changes and a reduction in bacterial diversity.
- ✓ *Faecalibacterium prausnitzii* appears to have a protective role in established adult Crohn's disease.

### WHAT IS NEW HERE

- ✓ Phylum-level bacterial changes are not important in pediatric inflammatory bowel disease (IBD) at diagnosis.
- ✓ Bacterial diversity is reduced in *de-novo* pediatric Crohn's disease but not in ulcerative colitis.
- ✓ *Faecalibacterium prausnitzii* is increased in the colonic mucosa of newly diagnosed Crohn's disease, suggesting a more complex role for the organism.

## REFERENCES

1. Benchimol EI, Fortinsky KJ, Gozdyra P *et al*. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. *Inflamm Bowel Dis* 2011;17:423–39.
2. Molodecky NA, Soon IS, Rabi DM *et al*. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. *Gastroenterology* 2012;142:46–54.
3. Henderson P, Hansen R, Cameron FL *et al*. Rising incidence of pediatric inflammatory bowel disease in Scotland. *Inflamm Bowel Dis* 2012;18:999–1005.
4. Travassos LH, Carneiro LAM, Ramjeet M *et al*. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. *Nat Immunol* 2009;11:55–62.
5. Cooney R, Baker J, Brain O *et al*. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. *Nat Med* 2009;16:90–7.
6. Guarner F, Malagelada JR. Gut flora in health and disease. *Lancet* 2003;361:512–9.
7. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. *Nat Rev Immunol* 2009;9:313–23.
8. Swidsinski A, Ladhoff A, Pernthaler A *et al*. Mucosal flora in inflammatory bowel disease. *Gastroenterology* 2002;122:44–54.
9. Ott SJ, Musfeldt M, Wenderoth DF *et al*. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. *Gut* 2004;53:685–93.
10. Conte MP, Schippa S, Zamboni I *et al*. Gut-associated bacterial microbiota in paediatric patients with inflammatory bowel disease. *Gut* 2006;55:1760–7.
11. Sokol H, Lay C, Seksik P, Tannock GW. Analysis of bacterial bowel communities of IBD patients: What has it revealed? *Inflamm Bowel Dis* 2008;14:858–67.
12. Mukhopadhyay I, Hansen R, El-Omar EM, Hold GL. IBD- what role do proteobacteria play? *Nat Rev Gastroenterol Hepatol* 2012;9:219–30.
13. Eckburg PB, Bik EM, Bernstein CN *et al*. Diversity of the human intestinal microbial flora. *Science* 2005;308:1635–8.
14. Momozawa Y, Deffontaine V, Louis E, Medrano JF. Characterization of bacteria in biopsies of colon and stools by high throughput sequencing of the V2 region of bacterial 16S rRNA gene in human. *PLoS ONE* 2011;6:e16952.
15. Lennard-Jones JE. Classification of inflammatory bowel disease. *Scand J Gastroenterol* 1989;24:2–6.
16. IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis—the porto criteria. *JPGN* 2005;41:1–7.
17. Silverberg MS, Satsangi J, Ahmad T *et al*. Towards an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a working party of the 2005 montreal world congress of gastroenterology. *Can J Gastroenterol* 2005;19 (Suppl A): 5A–36A.
18. Levine A, Griffiths A, Markowitz J *et al*. Pediatric modification of the montreal classification for inflammatory bowel disease: The Paris classification. *Inflamm Bowel Dis* 2011;17:1314–21.
19. Thomson JM, Hansen R, Berry SH *et al*. Enterohepatic helicobacter in ulcerative colitis: potential pathogenic entities? *PLoS ONE* 2011;6:e17184.
20. Hold GL, Pryde SE, Russell VJ, Furrer E, Flint HJ. Assessment of microbial diversity in human colonic samples by 16S rDNA sequence analysis. *FEMS Microbiol Ecol* 2002;39:33–9.
21. Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. *PLoS Biol* 2008;6:e280.
22. Ramirez-Farias C, Slezak K, Fuller Z, Duncan A, Holtrop G, Louis P. Effect of inulin on the human gut microbiota: Stimulation of bifidobacterium adolescentis and faecalibacterium prausnitzii. *Br J Nutr* 2009;101:533–42.
23. Bibiloni R, Mangold M, Madsen KL, Fedorak RN, Tannock GW. The bacteriology of biopsies differs between newly diagnosed, untreated, crohn's disease and ulcerative colitis patients. *J Med Microbiol* 2006;55:1141–9.
24. Doktor MJ, Paster BJ, Abramowicz S *et al*. Alterations in diversity of the oral microbiome in pediatric inflammatory bowel disease. *Inflamm Bowel Dis*. 2011;18:935–42.
25. Sepehri S, Kotlowski R, Bernstein CN, Krause DO. Microbial diversity of inflamed and noninflamed gut biopsy tissues in inflammatory bowel disease. *Inflamm Bowel Dis* 2007;13:675–83.
26. Ott SJ, Plamondon S, Hart A *et al*. Dynamics of the mucosa-associated flora in ulcerative colitis during remission and clinical relapse. *J Clin Microbiol* 2008;46:3510–3.
27. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. *PNAS* 2007;104:13780–5.
28. Walker AW, Sanderson JD, Churcher C *et al*. High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. *BMC Microbiol* 2011;11:7.
29. Willing B, Dicksved J, Halfvarson J *et al*. A pyrosequencing study in twins shows that GI microbial profiles vary with inflammatory bowel disease phenotypes. *Gastroenterology* 2010;139:1844–54.
30. Imielinski M, Baldassano RN, Griffiths A *et al*. Common variants at five new loci associated with early-onset inflammatory bowel disease. *Nat Genet* 2009;41:1335–40.
31. Van Limbergen J, Russell RK, Drummond HE *et al*. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. *Gastroenterology* 2008;135:1114–22.
32. Kugathasan S, Saubermann LJ, Smith L *et al*. Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease. *Gut* 2007;56:1696–705.
33. Michail S, Durbin M, Turner D *et al*. Alterations in the gut microbiome of children with severe ulcerative colitis. *Inflamm Bowel Dis* 2012;18:1799–808.
34. Sokol H, Pigneur B, Watterlot L *et al*. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. *PNAS* 2008;105:16731–6.
35. Sokol H, Seksik P, Furet JP *et al*. Low counts of faecalibacterium prausnitzii in colitis microbiota. *Inflamm Bowel Dis* 2009;15:1183–9.
36. Medina C, Santana A, Llopis M *et al*. Induction of colonic transmural inflammation by *Bacteroides fragilis*. Implication of matrix metalloproteinases. *Inflamm Bowel Dis* 2005;11:99–105.
37. Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. *Nature* 2008;453:620–5.
38. Round JL, Mazmanian SK. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. *PNAS* 2010;107:12204–9.
39. Jia W, Whitehead RN, Griffiths L *et al*. Is the abundance of *Faecalibacterium prausnitzii* relevant to Crohn's disease? *FEMS Microbiol Lett* 2010;310:138–44.
40. Buchanan E, Gaunt W, Cardigan T, Garrick V, McGrogan P, Russell R. The use of exclusive enteral nutrition for induction of remission in children with Crohn's disease demonstrates that disease phenotype does not influence clinical remission. *Aliment Pharmacol Ther* 2009;30:501–7.

41. Otley AR, Russell RK, Day AS. Nutritional therapy for the treatment of pediatric Crohns disease. *Expert Rev Clin Immunol* 2010; 6:667–76.
42. Benus R, van der Werf TS, Welling GW *et al.* Association between faecalibacterium prausnitzii and dietary fibre in colonic fermentation in healthy human subjects. *Br J Nutr* 2010;104:693–700.
43. Griffiths AM. Enteral feeding in inflammatory bowel disease. *Curr Opin Clin Nutr Metab Care* 2006;9:314–8.
44. Khan MT, Duncan SH, Stams AJM, van Dijk JM, Flint HJ, Harmsen HJM. The gut anaerobe faecalibacterium prausnitzii uses an extracellular electron shuttle to grow at oxic-anoxic interphases. *ISME J* 2012;6:1578–85.
45. Huttenhower C, Gevers D, Knight R *et al.* Structure, function and diversity of the healthy human microbiome. *Nature* 2012; 486:207–14.
46. Methé BA, Nelson KE, Pop M *et al.* A framework for human microbiome research. *Nature* 2012;486:215–21.
47. Walker AW, Duncan SH, McWilliam Leitch EC, Child MW, Flint HJ. pH and peptide supply can radically alter bacterial populations and short-chain fatty acid ratios within microbial communities from the human colon. *Appl Environ Microbiol* 2005;71:3692–700.
48. Sghir A, Gramet G, Suau A, Rochet V, Pochart P, Dore J. Quantification of bacterial groups within human fecal flora by oligonucleotide probe hybridization. *Appl Environ Microbiol* 2000;66:2263–6.



This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-sa/3.0/>